Pediatric Nephrology

, Volume 9, Issue 3, pp 382–385

Invited Review Recognition and management of angiotensin converting enzyme inhibitor fetopathy

  • Aileen B. Sedman
  • David B. Kershaw
  • Timothy E. Bunchman
Article

DOI: 10.1007/BF02254221

Cite this article as:
Sedman, A.B., Kershaw, D.B. & Bunchman, T.E. Pediatr Nephrol (1995) 9: 382. doi:10.1007/BF02254221

Abstract

Angiotensin converting enzyme (ACE) inhibitors are extensively used for the treatment of hypertension, to decrease proteinuria, and to mitigate hyperfiltration. These drugs now have been shown to be fetotoxic causing profound fetal hypotension, renal tubular dysplasia, anuria-oligohydramnios, growth restriction, hypocalvaria, and death when used in the second and third trimesters of pregnancy. We recommend that ACE inhibitors not be used in pregnancy. However, if a child is born with ACE inhibitor fetopathy, aggressive therapy with dialysis to remove the inhibitor may mitigate the profound hypotensive effects. Therapy will depend on the specific ACE inhibitor, and care recommendations cannot be generalized for the entire class of drugs as their protein binding and volume of distribution differ substantially.

Key words

Angiotensin converting enzyme inhibitors Fetopathy Therapy 

Copyright information

© IPNA 1995

Authors and Affiliations

  • Aileen B. Sedman
    • 1
  • David B. Kershaw
    • 1
  • Timothy E. Bunchman
    • 1
  1. 1.Pediatric Nephrology ServiceUniversity of Michigan Medical CenterAnn ArborUSA

Personalised recommendations